Compare drug alternatives

Bimzelx® Alternatives

Bimzelx®(bimekizumab-bkzx)
Taltz®(ixekizumab)
Prescription Only
Bimzelx (bimekizumab) is a medication classified as an interleukin inhibitor, prescribed for the treatment of certain types of plaque psoriasis in adults. It functions by reducing...
Prescription Only
Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its...
Dosage & Administration
Administration
Subcutaneous. Learn more.
Subcutaneous Injection. Learn more.
Dosing
The recommended dosage of BIMZELX is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.. Learn more.
Recommended dosage is 80 mg by subcutaneous injection every 4 weeks.. Learn more.
Latin Shorthand
The recommended dosage of BIMZELX is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.. Learn more.
80mg SC inj. Q4W. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
$5 or $15. Learn more.
Annual Cap
$9,100. Learn more.
Assistance Expiration
2 years. Learn more.
12/31/2025 or 36 months from qualification, whichever comes first (with prior authorization and appeal process as required). Learn more.
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
The following adverse reactions have been observed with BIMZELX and are discussed in greater detail in other sections of the labeling: Suicidal Ideation and Behavior [see Warnings and Precautions (5.1)] Infections [see Warnings and Precautions (5.2)] Liver Biochemical Abnormalities [see Warnings and Precautions (5.4)] Inflammatory Bowel Disease [see Warnings and Precautions (5.5)]. Learn more.
Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.. Learn more.
Mechanism of Actions (MoA)
Interleukin 17A and Interleukin 17F Antagonist. Learn more.
Interleukin 17A Antagonists. Learn more.
Special Populations
What is the Pregnancy Exposure Registry?

It is a registry that monitors pregnancy outcomes in women exposed to TALTZ during pregnancy.

How can pregnant women enroll in the TALTZ Pregnancy Registry?

Pregnant women exposed to TALTZ can enroll in the registry by calling 1-800-284-1695. Contact information for the registry is also available on https://www.taltz.com.

What is the risk associated with TALTZ use in pregnant women?

Available data from the published literature and the pharmacovigilance database with TALTZ use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

Is there a risk of harm to the developing fetus with TALTZ use in pregnant women?

An embryofetal development study conducted in pregnant monkeys during organogenesis at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD. However, the clinical significance of these nonclinical findings is unknown.

What is the background risk of major birth defects and miscarriage in the U.S. general population?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies in the U.S. general population is 2 to 4% and 15 to 20%, respectively.

Is TALTZ present in human milk and what are its effects on breastfed infants?

There are no available data on the presence of ixekizumab (TALTZ) in human milk, the effects on the breastfed infant, or the effects on milk production. However, ixekizumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition.

Is TALTZ safe and effective for use in pediatric patients?

TALTZ is approved for use in pediatric patients aged 6-18 years with moderate-to-severe plaque psoriasis. Its safety and effectiveness have not been established in other pediatric indications or in patients less than 6 years of age.